Holen Sie sich die Stockscreener-App
1.13
7.38%
-0.09
Schlusskurs vom Vortag:
$1.22
Offen:
$1.22
24-Stunden-Volumen:
58,426
Relative Volume:
0.98
Marktkapitalisierung:
$128.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.85M
KGV:
-0.07
EPS:
-16.1435
Netto-Cashflow:
$-15.72M
1W Leistung:
-15.04%
1M Leistung:
-65.76%
6M Leistung:
-49.33%
1J Leistung:
+206.23%
1-Tages-Spanne:
$1.0801
$1.22
1-Wochen-Bereich:
$0.92
$1.38
52-Wochen-Spanne:
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Firmenname
Indaptus Therapeutics Inc
Sektor
Branche
Telefon
(646) 427-2727
Adresse
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
1.1307 | 138.16M | 0 | -20.85M | -15.72M | -16.14 |
VRTX
Vertex Pharmaceuticals Inc
|
436.73 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.57 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.44 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.70 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.28 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Indaptus Therapeutics Inc Aktie (INDP) Neueste Nachrichten
Indaptus Therapeutics Q4 2025 Earnings: EPS Misses Estimates on Minimal Revenue, Stock Surges - Newser
Indaptus Therapeutics Inc. (INDP) Q4 2025 Earnings: Deeper Loss, Yet Shares Surge on Pipeline ProgressRevenue Warning Signal - Newser
Indaptus Therapeutics (INDP) Surges 15%: Biotech Stock Breaks Above Key ResistanceMarket Hype Signals - Newser
Earnings Scheduled For May 15, 2026 - Sahm
Indaptus Therapeutics, Inc. Reports Substantial Doubt About Going Concern and Highlights Key Risks in Q1 2026 10-Q Filing - Minichart
Indaptus Therapeutics Reports Q1 2026 Financial Results, Management Changes, and Strategic Review Amid Cash Constraints - Minichart
Indaptus Therapeutics reassesses decoy platform as cash dwindles - grafa.com
Indaptus Therapeutics Q1 Financial Analysis - Intellectia AI
Indaptus Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Indaptus Therapeutics (NASDAQ: INDP) cuts R&D, warns on cash runway - Stock Titan
Cash drops at Indaptus (Nasdaq: INDP) as Q1 2026 loss narrows - Stock Titan
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics Q1 net loss narrows as expenses fall - TradingView
Press Release: Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
INDP Should I Buy - Intellectia AI
TradingKey - TradingKey
INDP | Indaptus Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Indaptus Therapeutics Company Profile & Introduction - Moomoo
INDP Q1'26 Earnings: EPS estimate is (1.87) USD - TradingView
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Large holders in Indaptus (INDP) revise stakes and end group status - Stock Titan
Indaptus Therapeutics (INDP) Stock: Is It a Good Entry Point | Indaptus Therapeutics misses EPS views, no revenue - newser.com
Is It a Good Entry Point | Indaptus Therapeutics misses EPS views, no revenueVerified Stock Signals - Newser
Indaptus Therapeutics Appoints Tim Ruan and Johnny Fox Arrowsmith as Independent Directors; Amendment Reflects Legal Name Change - Minichart
Indaptus Therapeutics (INDP) refreshes board with two independents as one resigns - Stock Titan
Indaptus Therapeutics (INDP) reshapes board with two new independents and one exit - Stock Titan
Indaptus Therapeutics Adds Independent Directors Amid Board Refresh - TipRanks
Indaptus Therapeutics appoints two new independent directors and announces board changes By Investing.com - Investing.com South Africa
Indaptus Therapeutics appoints two new independent directors and announces board changes - Investing.com
Indaptus Therapeutics names Tim Ruan and Yi Zhang as independent directors; Matthew McMurdo resigns - TradingView
Indaptus (INDP) director Lu Qinglai submits initial Form 3 ownership - Stock Titan
Is Indaptus Therapeutics (INDP) stock trading at a premium valuation (Momentum Building) 2026-04-20Crowd Signals - Newser
Indaptus Therapeutics (INDP) Stock: Why Automation Investment (Soars) 2026-04-18Trend Analysis - Xã Châu Thành
Sino Lion Ventures Ltd Net Worth (2026) - GuruFocus
Junyi Dai Net Worth (2026) - GuruFocus
Yun Yao Net Worth (2026) - GuruFocus
Momentum Shift: Should I hold or sell Indaptus Therapeutics Inc nowInflation Watch & Daily Stock Trend Watchlist - baoquankhu1.vn
Published on: 2026-04-13 10:12:55 - baoquankhu1.vn
[SCHEDULE 13G/A] Indaptus Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Risk Off: Why is Indaptus Therapeutics Inc stock going up2026 Volume Leaders & High Yield Equity Trading Tips - baoquankhu1.vn
Will Indaptus Therapeutics (INDP) Stock Outperform S&P 500 | Price at $1.54, Down 3.75%New Highs New Lows - Newser
Indaptus Therapeutics Appoints Yu Ding as New Chief Financial Officer Effective April 2026 - Minichart
Indaptus Therapeutics Names New CFO, Refreshes Board Oversight - The Globe and Mail
Indaptus Therapeutics announces CFO transition and new board appointment - Investing.com
INDP Technical Analysis & Stock Price Forecast - Intellectia AI
Indaptus Therapeutics announces CFO transition and new board appointment By Investing.com - Investing.com South Africa
Indaptus appoints Yu Ding as CFO; Nir Sassi resigns - TradingView — Track All Markets
Indaptus Therapeutics (INDP) names new CFO and independent director - Stock Titan
Indaptus Therapeutics Inc. (INDP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Yun Yao converts preferred into 41.99M Indaptus (INDP) shares - Stock Titan
Finanzdaten der Indaptus Therapeutics Inc-Aktie (INDP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):